Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review

Parteek Prasher; Mousmee Sharma; Alaa A. A. Aljabali; Gaurav Gupta; Poonam Negi; Deepak N. Kapoor; Inderbir Singh; Flavia C. Zacconi; Terezinha Jesus Andreoli Pinto; Mateus  Webba Da Silva; Hamid A. Bakshi; Dinesh Kumar Chellappan; Murtaza M. Tambuwala; Kamal Dua

doi:10.1002/ddr.21704

Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review

Parteek Prasher, Mousmee Sharma, Alaa A. A. Aljabali, Gaurav Gupta, Poonam Negi, Deepak N. Kapoor, Inderbir Singh, Flavia C. Zacconi, Terezinha Jesus Andreoli Pinto, Mateus Webba Da Silva, Hamid A. Bakshi, Dinesh Kumar Chellappan, Murtaza M. Tambuwala, Kamal Dua

School of PharmacySuresh Gyan Vihar University Jaipur Rajasthan India
Departamento de Organica, faculdad de Quimica y de Farmacia, Pontificia Universidad Catolica de Chile Santiago Chile
Department of Life Sciences, School of PharmacyInternational Medical University, Bukit Jalil Kuala Lumpur Malaysia
Discipline of Pharmacy, Graduate School of HealthUniversity of Technology Sydney Ultimo New South Wales Australia

Research output: Contribution to journal › Review article › peer-review

27 Citations (Scopus)

658 Downloads (Pure)

Abstract

Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.

Original language	English
Pages (from-to)	837-858
Number of pages	22
Journal	Drug Development Research
Volume	81
Issue number	7
Early online date	24 Jun 2020
DOIs	https://doi.org/10.1002/ddr.21704
Publication status	Published (in print/issue) - 10 Nov 2020

Bibliographical note

Funding Information:
P. P. thanks the Department of Chemistry, University of Petroleum & Energy Studies (UPES), M. S. thanks the Department of Chemistry, Uttaranchal University (UU), The authors duly acknowledge Department of Chemistry, Guru Nanak Dev University (GNDU) for providing requisite resources for completing this work. G. G., D. N. K. thank Department of Pharmacy, Shoolini University for resources. D. K. C. thanks IMU, Malaysia for research infrastructure. M. M. T. and K. D. thanks Ulster University and University of Technology Sydney for providing research facilities.

Publisher Copyright:
© 2020 Wiley Periodicals, lnc.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Funding

Funding Information: P. P. thanks the Department of Chemistry, University of Petroleum & Energy Studies (UPES), M. S. thanks the Department of Chemistry, Uttaranchal University (UU), The authors duly acknowledge Department of Chemistry, Guru Nanak Dev University (GNDU) for providing requisite resources for completing this work. G. G., D. N. K. thank Department of Pharmacy, Shoolini University for resources. D. K. C. thanks IMU, Malaysia for research infrastructure. M. M. T. and K. D. thanks Ulster University and University of Technology Sydney for providing research facilities. Publisher Copyright: © 2020 Wiley Periodicals, lnc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

1,3,5-triazine
anti-Alzheimer's activity
anti-inflammatory activity
anticancer activity
antimicrobial activity
antiplasmodial activity
hybrids
multidrug-resistance

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ddr.21704

REVISED Manuscript DDRAuthor Accepted Manuscript, 733 KB

Cite this

Prasher, P., Sharma, M., Aljabali, A. A. A., Gupta, G., Negi, P., Kapoor, D. N., Singh, I., Zacconi, F. C., Jesus Andreoli Pinto, T., Webba Da Silva, M., Bakshi, H. A., Chellappan, D. K., Tambuwala, M. M., & Dua, K. (2020). Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review. Drug Development Research, 81(7), 837-858. https://doi.org/10.1002/ddr.21704

@article{b4a6973742664e3da2912752a5d379bd,

title = "Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review",

abstract = "Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.",

keywords = "1,3,5-triazine, anti-Alzheimer's activity, anti-inflammatory activity, anticancer activity, antimicrobial activity, antiplasmodial activity, hybrids, multidrug-resistance",

author = "Parteek Prasher and Mousmee Sharma and Aljabali, \{Alaa A. A.\} and Gaurav Gupta and Poonam Negi and Kapoor, \{Deepak N.\} and Inderbir Singh and Zacconi, \{Flavia C.\} and \{Jesus Andreoli Pinto\}, Terezinha and \{Webba Da Silva\}, Mateus and Bakshi, \{Hamid A.\} and Chellappan, \{Dinesh Kumar\} and Tambuwala, \{Murtaza M.\} and Kamal Dua",

note = "Funding Information: P. P. thanks the Department of Chemistry, University of Petroleum \& Energy Studies (UPES), M. S. thanks the Department of Chemistry, Uttaranchal University (UU), The authors duly acknowledge Department of Chemistry, Guru Nanak Dev University (GNDU) for providing requisite resources for completing this work. G. G., D. N. K. thank Department of Pharmacy, Shoolini University for resources. D. K. C. thanks IMU, Malaysia for research infrastructure. M. M. T. and K. D. thanks Ulster University and University of Technology Sydney for providing research facilities. Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals, lnc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = nov,

day = "10",

doi = "10.1002/ddr.21704",

language = "English",

volume = "81",

pages = "837--858",

journal = "Drug Development Research",

issn = "0272-4391",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "7",

}

Prasher, P, Sharma, M, Aljabali, AAA, Gupta, G, Negi, P, Kapoor, DN, Singh, I, Zacconi, FC, Jesus Andreoli Pinto, T, Webba Da Silva, M, Bakshi, HA, Chellappan, DK, Tambuwala, MM & Dua, K 2020, 'Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review', Drug Development Research, vol. 81, no. 7, pp. 837-858. https://doi.org/10.1002/ddr.21704

TY - JOUR

T1 - Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review

AU - Prasher, Parteek

AU - Sharma, Mousmee

AU - Aljabali, Alaa A. A.

AU - Gupta, Gaurav

AU - Negi, Poonam

AU - Kapoor, Deepak N.

AU - Singh, Inderbir

AU - Zacconi, Flavia C.

AU - Jesus Andreoli Pinto, Terezinha

AU - Webba Da Silva, Mateus

AU - Bakshi, Hamid A.

AU - Chellappan, Dinesh Kumar

AU - Tambuwala, Murtaza M.

AU - Dua, Kamal

N1 - Funding Information: P. P. thanks the Department of Chemistry, University of Petroleum & Energy Studies (UPES), M. S. thanks the Department of Chemistry, Uttaranchal University (UU), The authors duly acknowledge Department of Chemistry, Guru Nanak Dev University (GNDU) for providing requisite resources for completing this work. G. G., D. N. K. thank Department of Pharmacy, Shoolini University for resources. D. K. C. thanks IMU, Malaysia for research infrastructure. M. M. T. and K. D. thanks Ulster University and University of Technology Sydney for providing research facilities. Publisher Copyright: © 2020 Wiley Periodicals, lnc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/11/10

Y1 - 2020/11/10

N2 - Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.

AB - Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.

KW - 1,3,5-triazine

KW - anti-Alzheimer's activity

KW - anti-inflammatory activity

KW - anticancer activity

KW - antimicrobial activity

KW - antiplasmodial activity

KW - hybrids

KW - multidrug-resistance

UR - https://www.scopus.com/pages/publications/85087217639

U2 - 10.1002/ddr.21704

DO - 10.1002/ddr.21704

M3 - Review article

C2 - 32579723

SN - 0272-4391

VL - 81

SP - 837

EP - 858

JO - Drug Development Research

JF - Drug Development Research

IS - 7

ER -

Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Molecular analysis of the effects of crocin on acute myeloid leukaemia, pancreatic and colon cancer

Cite this

Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Student theses

Molecular analysis of the effects of crocin on acute myeloid leukaemia, pancreatic and colon cancer

Cite this